181 related articles for article (PubMed ID: 25395875)
21. The Quality of Life Questionnaire Core 30 (QLQ-C30) and Functional Assessment of Cancer-General (FACT-G) differ in responsiveness, relative efficiency, and therefore required sample size.
King MT; Bell ML; Costa D; Butow P; Oh B
J Clin Epidemiol; 2014 Jan; 67(1):100-7. PubMed ID: 24125895
[TBL] [Abstract][Full Text] [Related]
22. Value of quality of life analysis in liver cancer: A clinician's perspective.
Li L; Yeo W
World J Hepatol; 2017 Jul; 9(20):867-883. PubMed ID: 28804570
[TBL] [Abstract][Full Text] [Related]
23. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ;
Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338
[TBL] [Abstract][Full Text] [Related]
24. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
25. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
[TBL] [Abstract][Full Text] [Related]
26. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
[No Abstract] [Full Text] [Related]
27. Validating and improving the reliability of the EORTC qlq-c30 using a multidimensional Rasch model.
Shih CL; Chen CH; Sheu CF; Lang HC; Hsieh CL
Value Health; 2013; 16(5):848-54. PubMed ID: 23947980
[TBL] [Abstract][Full Text] [Related]
28. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
30. Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.
Gough N; Koffman J; Ross JR; Riley J; Judson I
PLoS One; 2019; 14(9):e0210731. PubMed ID: 31557183
[TBL] [Abstract][Full Text] [Related]
31. Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.
Jang RW; Isogai PK; Mittmann N; Bradbury PA; Shepherd FA; Feld R; Leighl NB
J Thorac Oncol; 2010 Dec; 5(12):1953-7. PubMed ID: 21155140
[TBL] [Abstract][Full Text] [Related]
32. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
[TBL] [Abstract][Full Text] [Related]
33. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires.
Pezzilli R; Morselli-Labate AM; Fantini L; Campana D; Corinaldesi R
Dig Liver Dis; 2007 Dec; 39(12):1077-86. PubMed ID: 17692582
[TBL] [Abstract][Full Text] [Related]
35. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
36. Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients.
McLachlan SA; Devins GM; Goodwin PJ
Eur J Cancer; 1998 Mar; 34(4):510-7. PubMed ID: 9713301
[TBL] [Abstract][Full Text] [Related]
37. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30): validation of English version in Singapore.
Luo N; Fones CS; Lim SE; Xie F; Thumboo J; Li SC
Qual Life Res; 2005 May; 14(4):1181-6. PubMed ID: 16041912
[TBL] [Abstract][Full Text] [Related]
38. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
[TBL] [Abstract][Full Text] [Related]
39. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
[TBL] [Abstract][Full Text] [Related]
40. Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning.
Petersen MA; Groenvold M; Aaronson NK; Chie WC; Conroy T; Costantini A; Fayers P; Helbostad J; Holzner B; Kaasa S; Singer S; Velikova G; Young T;
Eur J Cancer; 2010 May; 46(8):1352-8. PubMed ID: 20231085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
